Want to see EVH full AI Analyst Report?
EVH Stock Chart & Stats
$4.22
$0.00(0.00%)
At close: 4:00 PM EDT
$4.22
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$2.10 - $10.08
Previous CloseN/A
Volume827.94K
Average Volume (3M)2.67M
Market Cap
$529.12M
Enterprise Value$1.44K
Total Cash (Recent Filing)$115.70M
Total Debt (Recent Filing)$970.43M
Price to Earnings (P/E)―
Beta0.59
Next Earnings
Nov 04, 2026EPS Estimate
0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.49
Shares Outstanding113,059,330
10 Day Avg. Volume3,303,213
30 Day Avg. Volume2,668,208
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.10
Price to Sales (P/S)0.24
P/FCF Ratio96.07
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$5.80Price Target Upside37.44% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)0.17
Revenue Forecast (FY)$2.62B
Bulls Say, Bears Say
Bulls Say
Raised Growth And EBITDA OutlookHigher guidance indicates stronger demand, successful program launches and improving operating execution. The outlook also supports a durable scaling trajectory, provided Evolent converts expected revenue growth into consistent profitability and cash generation.
Large Oncology Partnership Expands Contracted PlatformA large specialty-care contract can expand Evolent’s covered lives, deepen its health-plan relationships and increase recurring program revenue. Oncology also reinforces the company’s positioning in complex, high-cost specialties where clinical management can create customer value.
AI Automation Is Improving Clinical Workflow EfficiencyScaling automation can lower administrative costs, accelerate care decisions and improve service consistency for health-plan customers. Broader adoption may support margin improvement and strengthen Evolent’s technology-enabled differentiation over the next several quarters.
Bears Say
Deep Losses And Sustained Margin PressurePersistent net losses and lower gross margins show that revenue growth has not yet translated into durable economic profitability. Continued cost-of-services pressure or unfavorable mix could limit reinvestment capacity and weaken the credibility of longer-term EBITDA targets.
High Net Debt And Limited Cash-flow CoverageElevated leverage increases refinancing and execution risk, especially because projected operating cash flow covers only a small portion of interest obligations. Until profitability and cash conversion improve, debt service may constrain investment and strategic flexibility.
Membership And Medical-cost Headwinds Threaten Future GrowthLower Medicaid and exchange membership can reduce covered lives and pressure revenue across contracted programs, while elevated medical expense ratios can reduce economics on risk-bearing arrangements. These forces create a structural challenge to growth and margin recovery.
Evolent Health News
EVH FAQ
What was Evolent Health Inc.’s price range in the past 12 months?
Evolent Health Inc. lowest stock price was $2.10 and its highest was $10.08 in the past 12 months.
What is Evolent Health Inc.’s market cap?
Evolent Health Inc.’s market cap is $529.12M.
When is Evolent Health Inc.’s upcoming earnings report date?
Evolent Health Inc.’s upcoming earnings report date is Nov 04, 2026 which is in 78 days.
How were Evolent Health Inc.’s earnings last quarter?
Evolent Health Inc. released its earnings results on Aug 06, 2026. The company reported $0.02 earnings per share for the quarter, beating the consensus estimate of -$0.01 by $0.03.
Is Evolent Health Inc. overvalued?
According to Wall Street analysts Evolent Health Inc.’s price is currently Undervalued.
Does Evolent Health Inc. pay dividends?
Evolent Health Inc. does not currently pay dividends.
What is Evolent Health Inc.’s EPS estimate?
Evolent Health Inc.’s EPS estimate is 0.06.
How many shares outstanding does Evolent Health Inc. have?
Evolent Health Inc. has 113,059,330 shares outstanding.
What happened to Evolent Health Inc.’s price movement after its last earnings report?
Evolent Health Inc. reported an EPS of $0.02 in its last earnings report, beating expectations of -$0.01. Following the earnings report the stock price went up 16.558%.
Which hedge fund is a major shareholder of Evolent Health Inc.?
Currently, no hedge funds are holding shares in EVH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Evolent Health Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.80 (37.44% Upside)
$5.80 (37.44% Upside)
Blogger Sentiment
Bullish
EVH Sentiment 80%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 86.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 0.8%
Last 30 Days ▼ 0.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-54.86%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-19.89%
Trailing 12-Months
Company Description
Evolent Health Inc.
Evolent Health, Inc., a prominent healthcare firm, operates through its subsidiary, Evolent Health LLC, to furnish clinical and administrative solutions to both healthcare payers and providers across the United States. Its operations are divided into two principal segments: Evolent Health Services and Clinical Solutions. The Evolent Health Services division delivers an integrated platform encompassing both administrative and clinical functions, specifically designed for health plan management and the oversight of population health. This includes essential financial and administrative support, such as managing health plan operations, risk assessment, robust analytics and reporting, and strategic leadership. A cornerstone of this segment is "Identifi," its proprietary technology, which intelligently aggregates and analyzes data, streamlines care workflows, and actively engages patients, all with the aim of achieving patient-centered and cost-effective population health outcomes. Conversely, the Clinical Solutions segment specializes in offering sophisticated care management services for various stakeholders involved in specialty care delivery. These services are crucial for organizations transitioning from traditional fee-for-service models to value-based care, accommodating their unique stage of development and prevailing market dynamics, particularly in the fields of oncology and cardiology. The overarching objective of this segment is a holistic improvement in the total cost of care. Founded in 2011, Evolent Health, Inc. maintains its corporate headquarters in Arlington, Virginia.
EVH Company Deck
EVH Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed a balanced mix of strong operational execution and growth momentum (notably 31% QoQ revenue growth, a 50% jump in Performance Suite revenue, raised 2026 revenue guidance, a large oncology deal, and meaningful AI progress) alongside notable near-term challenges (elevated MER, membership headwinds from Medicaid/exchange, timing variability in EBITDA recognition, and elevated net leverage). Management expressed confidence in 2027 growth (>25% revenue) and margin recovery driven by AI, Performance Suite maturation and cost actions, but acknowledged material macro- and client-specific risks that temper near-term financial clarity.View all EVH earnings summariesEVH Stock 12 Month Forecast
Average Price Target
$5.80
▲(37.44% Upside)
Technical Analysis
Ownership Overview
2.82% Insiders
13.34% Mutual Funds
32.13% Other Institutional Investors
38.83% Public Companies and
Individual Investors